Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 20/20 | 1.00 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14276839 | 1.00 | SLC9A1 (1.00) | SLC9A1SLC9A2 | |
| SCHEMBL14276752 | 0.91 | SLC9A1 (1.00) | SLC9A1SLC9A2 | |
| SCHEMBL14276853 | 0.90 | SLC9A1 (1.00) | SLC9A1SLC9A2 | |
| SCHEMBL14276830 | 0.87 | SLC9A1 (0.80) | SLC9A1SLC9A2 | |
| SCHEMBL16588925 | 0.86 | SLC9A1 (0.76) | SLC9A1SLC9A2 | |
| SCHEMBL14276835 | 0.86 | SLC9A1 (0.85) | SLC9A1SLC9A2 | |
| SCHEMBL14276832 | 0.85 | SLC9A1 (0.77) | SLC9A1SLC9A2 | |
| SCHEMBL14276838 | 0.85 | SLC9A1 (0.74) | SLC9A1SLC9A2 | |
| SCHEMBL14276871 | 0.84 | SLC9A1 (0.72) | SLC9A1SLC9A2 | |
| SCHEMBL14276741 | 0.84 | SLC9A1 (1.00) | SLC9A1SLC9A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577202-A1 | USE OF A THERAPEUTIC AGENT WITH SODIUM-HYDROGEN ANTIPORTER 1 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | Mitodicure GmbH (DE) | 2025-07-02 | — | — | EP | claimed |
| CN-119923254-A | Use of therapeutic agents having sodium hydrogen antiport 1 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or fatigue intolerance | 米托迪治愈有限责任公司 | 2025-05-02 | — | — | CN | claimed |
| WO-2024042160-A1 | USE OF A THERAPEUTIC AGENT WITH SODIUM-HYDROGEN ANTIPORTER 1 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | MITODICURE GMBH (DE) | 2024-02-29 | — | — | WO | claimed |
| EP-4577202-A1 | USE OF A THERAPEUTIC AGENT WITH SODIUM-HYDROGEN ANTIPORTER 1 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | Mitodicure GmbH (DE) | 2025-07-02 | — | — | EP | disclosed |
| CN-119923254-A | Use of therapeutic agents having sodium hydrogen antiport 1 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or fatigue intolerance | 米托迪治愈有限责任公司 | 2025-05-02 | — | — | CN | disclosed |
| WO-2024042160-A1 | USE OF A THERAPEUTIC AGENT WITH SODIUM-HYDROGEN ANTIPORTER 1 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | MITODICURE GMBH (DE) | 2024-02-29 | — | — | WO | disclosed |